Satralizumab: First Approval - SAkuraStar and SAkuraSky clinical trial video abstracts

<p>SAKuraStar (NCT02073279) and SAkuraSky (NCT02028884) are two pivotal phase 3 randomized, placebo-controlled clinical trials that led to the <a href="https://adisjournals.figshare.com/articles/online_resource/Satralizumab_First_Approval/12762386"><b>first approval of satralizumab</b></a>, a humanized anti-interleukin-6 (IL-6) receptor monoclonal recycling antibody, for the treatment of neuromyelitis optica spectrum disorder (NMOSD).</p> <p>These video abstracts of <a href="https://adisjournals.figshare.com/ndownloader/files/24625103"><b>SAKuraStar</b></a> and <a href="https://adisjournals.figshare.com/ndownloader/files/24625661"><b>SAkuraSky</b></a> provide</p> <p><b>· </b> a brief overview of the pathophysiology of NMO and NMOSD, </p> <p><b>· </b> the mechanism of action of satralizumab in patients with this disorder and </p> <p><b>· </b> the key efficacy and tolerability outcomes for subcutaneous satralizumab 120 mg administered as monotherapy (in SAkuraStar) or as add-on therapy to baseline immunosuppressant therapy (SAkuraSky) in patients with NMO or NMOSD. </p> <p>These video abstracts, which have been peer reviewed and were uploaded to Figshare after the<b> <a href="https://link.springer.com/article/10.1007/s40265-020-01380-2">satralizumab AdisInsight Report</a> </b>was published, are sponsored by Roche.</p> <p></p>